Life Technologies, a provider of innovative life science solutions, announced a definitive agreement to acquire Ion Torrent for $375 million in cash and stock.
Read All CloseNew bioprocessing standards
from
molecule to market
Life Technologies is responding to the quest to improve the human condition by setting technology, product and safety standards for the worldwide production of biotherapeutics and vaccines.
Contact us at outlicensing@lifetech.com to learn more.
“The world's six biggest-selling drugs in 2014 will all be biotech products, underlining the importance of the sector for the global pharmaceuticals industry.”
– Forbes, June 17, 2009
New cell lines, heightened concerns about product safety, emerging biosimilars, and a vaccine industry shifting to cell culture–based production all point to a need for forward-thinking technology and product platforms. Leveraging core expertise in cell culture development, downstream purification, and rapid molecular-based contaminant testing, the Life Technologies Bioproduction group is providing workflow solutions today to a biopharmaceutical industry at the cusp of transforming traditional disease treatment.

Overcoming upstream and downstream bioprocess and analytics bottlenecks
What's New in Bioprocessing
Bioproduction Webinar Series
Bioprocess Solutions from
Molecule to Market
The biotherapeutics and vaccine production solutions from Life Technologies are offered under trusted industry-leading brands: GIBCO® and Applied Biosystems®. Products and services help solve everyday problems from improving cell line titers, optimizing media formulations, and scaling cell culture production, to performing same-day critical impurity analyses and reducing purification run times.
| The leader in... | ||
Cell Culture Media Development |
Protein Purification - Polish Ion Exchange |
Rapid Molecular Methods for Contaminant Testing |
![]() |
![]() |
|
To learn more about how Life Technologies is advancing biotherapeutics and vaccine production, contact BP@lifetech.com